Bispecific T-cell engagers for cancer immunotherapy

Immunology and Cell Biology

Volumn 93, Issue 3, 2015, Pages 290-296

  Huehls, Amelia M ^a   Coupet, Tiffany A ^a   Sentman, Charles L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 112; ANTINEOPLASTIC AGENT; BISPECIFIC T CELL ENGAGER; BLINATUMOMAB; CD133 ANTIGEN; CD3 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MT 110; MT 111; PROSTATE STEM CELL ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CANCER VACCINE; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN BINDING; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL KILLING; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DRUG STRUCTURE; HUMAN; IMMUNOLOGICAL SYNAPSE; LARGE CELL LYMPHOMA; MACROPHAGE; NONHODGKIN LYMPHOMA; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; ANIMAL; CLINICAL TRIAL (TOPIC); GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS; PROCEDURES;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; SINGLE-CHAIN ANTIBODIES; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES;

EID: 84925091940     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.93     Document Type: Review

References (50)

1. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014; 123: 2625-2635
2. Chmielewski M, Hombach AA, Abken H. Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells. Front Immunol 2013; 4: 371
3. Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-Target cell antibody. Nature 1985; 316: 354-356
4. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985; 314: 628-631
5. Lindhofer H, Hess J, Ruf P. Trifunctional triomab antibodies for cancer therapy. In: Kontermann RE (ed). Bispecific Antibodies. Springer-Verlag: Berlin Heidelberg, Germany, 2011
6. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/ light chain pairing in rat/mouse quadromas implications for a single-step purification of bispecific antibodies. J Immunol 1995; 155: 219-225
7. Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, et al. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy. J Immunol 1994; 152: 2385-2392
8. Klein JS, Gnanapragasam PNP, Galimidi RP, Foglesong CP, Anthony P, West J, et al. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad USA 2009; 106: 7385-7390
9. BrischweinK, ParrL, Pflanz S, Volkland J, Lumsden J, Klinger M, et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 2007; 30: 798-807
10. Amann M, D'Argouges S, Lorenczewski G, Brischwein K, Kischel R, Lutterbuese R, et al. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-Term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother 2009; 32: 452-464
11. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006; 43: 763-771
12. Osada T, Hsu D, Hammond S, Hobeika A, Devi G, Clay TM, et al. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer 2010; 102: 124-133
13. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000; 95: 2098-2103
14. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002; 100: 690-697
15. Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother 2009; 32: 341-352
16. Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- And BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci USA 2010; 107: 12605-12610
17. Torisu-Itakura H, Schoellhammer HF, Sim MS, Irie RF, Hausmann S, Raum T, et al. Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells. J Immunother 2011; 34: 597-605
18. Bohlen H, Manzke O, Patel B, Moldenhauer G, Dorken B, von Fliedner V, et al. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res 1993; 53: 4310-4314
19. Manzke O, Titzer S, Tesch H, Diehl V, Bohlen H. CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma. Cancer Immunol Immunother 1997; 45: 198-202
20. Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 1999; 293: 41-56
21. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005; 115: 98-104
22. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006; 43: 1129-1143
23. Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 1995; 92: 7021-7025
24. Feldmann A, Arndt C, TÖpfer K, Stamova S, Krone F, Cartellieri M, et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T Cells. J Immunol 2012; 189: 3249-3259
25. Friedrich M, Raum T, Lutterbuese R, Voelkel M, Deegen P, Rau D, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther 2012; 11: 2664-2673
26. Herrmann I, Baeuerle PA, Friedrich M, Murr A, Filusch S, Ruttinger D, et al. Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. PLoS ONE 2010; 5: e13474
27. Cioffi M, Dorado J, Baeuerle PA, Heeschen C. EpCAM/CD3-bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res 2012; 18: 465-474
28. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977
29. Brambell FWR, Hemmings WA, Morris IG. A Theoretical Model of ?-Globulin Catabolism. Nature 1964; 203: 1352-1355
30. Weir ANC, Nesbitt A, Chapman AP, Popplewell AG, Antoniw P, Lawson ADG. Formatting antibody fragments to mediate specific therapeutic functions. Biochem Soc Trans 2002; 30: 512-516
31. Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/ anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 2006; 55: 503-514
32. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119: 6226-6233
33. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29: 2493-2498
34. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69: 4941-4944
35. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel?. MAbs 2009; 1: 539-547
36. Schlegel P, Lang P, Zugmaier G, Ebinger M, Kreyenberg H, Witte KE, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 2014; 99: 1212-1219
37. Kufer P, Mack M, Gruber R, Lutterbuse R, Zettl F, Riethmuller G. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol Immunother 1997; 45: 193-197
38. Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, et al. Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct. Cancer Res 2007; 67: 3927-3935
39. Yamamoto K, Trad A, Baumgart A, Huske L, Lorenzen I, Chalaris A, et al. A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells. Biochem J 2012; 445: 135-144
40. Loffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T, et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 2003; 17: 900-909
41. Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, et al. Longterm follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012; 120: 5185-5187
42. Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013; 121: 5154-5157
43. Witthauer J, Schlereth B, Brischwein K, Winter H, Funke I, Jauch KW, et al. Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110. Breast Cancer Res Treat 2009; 117: 471-481
44. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9: 67-81
45. Chang SS. Overview of prostate-specific membrane antigen. Rev Urol 2004; 6: S13-S18
46. Lutterbuese R, Wissing S, Amann M, Baeuerle P, Kufer P (eds). Conversion of Cetuximab and Trastuzumab into T cell-engaging BiTE antibodies creates novel drug candidates with superior anti-Tumor activity, 99th AACR Annual Meeting 2008. San Diego, CA, USA
47. Rodland KD, Bollinger N, Ippolito D, Opresko LK, Coffey RJ, Zangar R, et al. Multiple mechanisms are responsible for transactivation of the epidermal growth factor receptor in mammary epithelial cells. J Biol Chem 2008; 283: 31477-31487
48. Zhang T, Sentman CL. Cancer immunotherapy using a bi-specific NK receptor- fusion protein that engages both T cells and tumor cells. Cancer Res 2011; 71: 2066-2076
49. Laszlo GS, Gudgeon CJ, Harrington KH, Dell'Aringa J, Newhall KJ, Means GD, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 2014; 123: 554-561
50. Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L, et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther 2014; 13: 1549-1557